As it prepared to launch its first oral oncology drug, Takeda Pharmaceuticals wanted to find a way to identify outliers — patients who had difficulty getting the medication they need for one reason or another. The company hoped to use the vast amounts of patient prescription and status data that pharmacies have at their disposal, reasoning that it could help identify people who were actively using its medication, as well as those who were stalled by benefits investigations or whose insurers were putting up barriers.

“The person who’s spending 20 days on benefits investigation status is a person who’s struggling to get on therapy,” says Rebecca Greenberg, director of field services and commercial systems at Takeda.

To read this article in full or to leave a comment, please click here